Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revolutionising the diagnosis of multiple Sclerosis with the first bioinformatic diagnostic kit that allows early detection with a simple blood test

Project description

A fast and accurate multiple sclerosis diagnosis

Multiple sclerosis (MS) presents a pressing global health challenge, affecting approximately 2.8 million people worldwide, with a significant impact on young adults in developed countries. The current diagnostic process takes an average of 1 year, resulting in delayed pharmacological treatment, irreversible damage and a worse prognosis. In this context, the EIC-funded ALA DIAGNOSTICS MS KIT will develop the first in vitro MS diagnostic kit. It boasts the distinction of being the only specific and clinically validated biomarker for MS detection in blood. With its non-invasive, fast, easy and cost-effective nature, the ALA DIAGNOSTICS MS KIT holds immense promise in facilitating early diagnosis, enabling timely treatment and potentially transforming the lives of countless individuals affected by this debilitating condition.

Objective

Multiple Sclerosis affects around 700,000 people in Europe and 2.8 million worldwide. It is the most common chronic neurological disease in young adults in developed countries, and the main cause of disability after traffic accidents.
Current diagnosis process takes one year (on average) which makes pharmacological treatment start late producing irreversible damage in patients and a worse prognosis. Combined with the high rate of misdiagnoses (20%), it leads to a healthcare cost of around €20 billion every year.
ALA DIAGNOSTICS is revolutionising MS diagnosis with the first MS diagnostic kit, based on our patented recombinant protein, which is the only specific and clinically validated biomarker that exists for the diagnosis of MS in blood. Our diagnostic test is fast, easy, cheap, non-invasive, suitable for early diagnosis of MS and easy to integrate into daily clinical routine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

ALA DIAGNOSTICS SL
Net EU contribution
€ 1 407 525,00
Address
CALLE CASTELLO 107 6 PISO
28006 Madrid
Spain
SME
Yes
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 010 750,00